

Instructions for Authors of European Journal of Microbiology and Immunology

European Journal of Microbiology and Immunology is an Open Access, online only journal. It publishes original research papers, review articles, results of prospective randomized trials, case studies, and PhD-thesis summaries. Papers are accepted on the basis of scientific significance and suitability for publication and on the understanding that they have not been published, submitted or accepted for publication elsewhere.

Peer review. Papers submitted for publication are subject to single blind peer review performed by two independent reviewers. Papers accepted for publication by the Editorial Board are subject to editorial revision.

Authorship. All persons designated as authors should qualify for authorship. Each author should have participated sufficiently in the work to take public responsibility for the content. The corresponding author affirms that he or she had access to all data from the study, both what is reported and what is unreported, and also that he or she had complete freedom to direct its analysis and its reporting, without influence from the sponsors. The corresponding author also affirms that there was no editorial direction or censorship from the sponsors. Preparation of drafts of manuscripts by employees of the sponsor who are not listed as authors is expressly prohibited.

Disclosure of financial relationships. Disclosure of financial relationships is required at the time of submission and provisional acceptance of all manuscripts, including original articles, reviews, and case studies. The authors are responsible for informing the Journal of any additional financial relationships that may arise prior to the date of publication of their paper. Financial support for the study is always disclosed at the end of the manuscript (before the References), whether from governmental, nonprofit, or commercial sources. Non-financial forms of support, such as drugs, analytic support, or other assistance with preparation of the manuscript, must also be acknowledged. All authors must individually disclose all financial relationships, whether or not directly related to the subject of their paper. Such reporting must include all equity ownership, profit-sharing agreements, royalties, patents, and research or other grants from private industry or closely affiliated nonprofit funds. For income from pharmaceutical companies, the purpose must be specified. Reporting should encompass the previous 36 months. If an author has no interests to disclose, this must be explicitly stated. The Editors will review all author statements of financial support to determine if there is evidence of bias from these sources. If it appears that there may be, then further review and possible rejection of the manuscript may occur. Authors are encouraged to contact the Editor at any stage in the manuscript review process if they believe that they have relationships that require review.

Permissions. It is the responsibility of the author(s) to obtain written permission for quotations, and for the reprinting of illustrations or tables.

Manuscript submission. Authors should submit their paper using the online manuscript submission and peer review system; Editorial Manager. Details are available online at <http://www.editorialmanager.com/eujmi>

Preparation of manuscripts. Manuscripts should be written in clear, concise, and grammatically correct English. They should be typed double-spaced with 2.5 cm (1 inch) wide margins. Pages should be numbered consecutively (in succession), the title page being page one. The order should be as follows: title page, abstract, keywords, text, funding sources, authors' contributions, conflicts of interest, acknowledgements, supporting information, notes, references, figure captions. The manuscript should be submitted in IBM compatible Word for Windows file.

Title should be a clear and concise statement of the contents in not more than 20 words. A short running title of no more than 50 characters should also be supplied. This is followed by the authors' full name, and the name of the institutions where the work has been done. The mailing address, e-mail address, phone and fax numbers of the corresponding author must also be given in a footnote to the first page.

Abstract should not exceed 200 words and should briefly outline the purpose, results (new findings supported by data) and conclusions of the study. Citations are to be avoided in the abstract.

Keywords should be added in a number between 5 and 10.

The text of the paper should be divided into **sections** with the headings: Introduction, Materials and Methods, Results, Discussion, Funding sources, Authors' contributions, Conflicts of interest, Acknowledgements, Supporting information, References.

Introduction should state briefly the nature, purpose, and reasoning of the work and cite recent important work by others.

*

Akadémiai Kiadó and the *European Journal of Microbiology and Immunology* are committed to the **protection of animal and human research subjects** and ethical practices in science publishing, therefore studies submitted to the journal must have been conducted in accordance with all applicable local and international standards. All authors must conform to the highest standards of ethical conduct in the submission of accurate data, acknowledging the work of others, and divulging potential conflicts of interests.

All empirical studies must have a short description on the ethics regarding the study. This should be placed at the very end of the Methods section, under a separate subheading of **Ethics**. It should contain information on the **ethical approval** of the study by the Institutional Review Board and – where applicable – the **informed consent** (or parental consent for those younger than 18 years of age) given by the participants of the study. If approval was not obtained, authors must explain why it was not required. An example:

Ethics

The study procedures were carried out in accordance with the Declaration of Helsinki. The Institutional Review Board of the [Name of the Institute] approved the study. All subjects were informed about the study and all provided informed consent. (If applicable: Parental consent was sought for those younger than 18 years of age.)

Approval from the relevant body is required for studies involving:

- Humans (either live or tissue), such as studies that are observational, survey-based, or include any personal data;
- Animals (either live or tissue), such as observational studies;
- Commercially unavailable cell lines;
- Field sampling;
- Potential biosafety implications.

*

At the end of the manuscript, before the References section, please add the following statements:

- **Funding sources:** State even if no funding was obtained by writing “Nothing declared” or “No financial support was received for this study” or any other similar statement.
- **Authors’ contribution:** Please specify each author’s contribution to the manuscript. Use the monograms of the authors and specify their roles in preparing the manuscript. You may use the following roles: study concept and design, analysis and interpretation of data, statistical analysis, obtained funding, study supervision, or any other specific role. Also state whether all authors had full access to all data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
- **Conflict of interest:** All authors are requested to disclose any actual or potential conflict of interest including any financial, personal or other relationships with other people or organizations within three years of beginning the work submitted that could inappropriately influence, or be perceived to influence, their work. Also state if no conflict of interest was present by writing “The authors declare no conflict of interest” or “The authors report no financial or other relationship relevant to the subject of this article” or any other similar statement.
- You may add an optional **Acknowledgements** section for any further information you wish to disclose.

References in the text should be cited by names only if they are part of the sentence: “Hilton [5] described earlier...,” otherwise they should be indicated by the reference number(s) in square brackets [3, 7, 12]. If there are more than two authors, the name of the first author should be used, followed by “et al.” List the references in order of appearance at the end of the paper. The style and punctuation of references should conform to that used in the journal, which is following the recommendations of MEDLINE/PubMed (for further details see https://www.nlm.nih.gov/bsd/uniform_requirements.html).

See the following examples:

- for journals:
Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med*. 2002;347:284-7.
More than six authors:
Rose ME, Huerbin MB, Melick J, Marion DW, Palmer AM, Schiding JK, et al. Regulation of interstitial excitatory amino acid concentrations after cortical contusion injury. *Brain Res*. 2002;935(1-2):40-6.
Ahead-of-print articles:
Yu WM, Hawley TS, Hawley RG, Qu CK. Immortalization of yolk sac-derived precursor cells. *Blood*. 2002 Nov 15;100(10):3828-31. Epub 2002 Jul 5.

- for books:
Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. *Medical microbiology*. 4th ed. St. Louis: Mosby; 2002.
Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. *Operative obstetrics*. 2nd ed. New York: McGraw-Hill; 2002.
- for chapters:
Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. *The genetic basis of human cancer*. New York: McGraw-Hill; 2002. p. 93-113.
- for conference papers:
Christensen S, Oppacher F. An analysis of Koza's computational effort statistic for genetic programming. In: Foster JA, Lutton E, Miller J, Ryan C, Tettamanzi AG, editors. *Genetic programming. EuroGP 2002: Proceedings of the 5th European Conference on Genetic Programming*; 2002 Apr 3-5; Kinsdale, Ireland. Berlin: Springer; 2002. p. 182-91.

Abbreviations and symbols. All abbreviations should be spelled out when first used in the text. Please highlight unusual symbols on the margin. Quantities should be expressed in SI units.

Footnotes should only be used if absolutely necessary.

Tables should be comprehensive to the reader without reference to the text. They should be submitted as separate files and have a concise heading each typed above the table. Tables are numbered consecutively with Arabic numerals. All tables should be referred to in the text, in consecutive order.

Figures (line drawings, diagrams, photographs) should be numbered consecutively with Arabic numerals and submitted as separate files, as JPEG or TIFF. All figures should be referred to in the text, in consecutive order.

Advertisements may be inserted at the rates of the Publisher.

Proofs. One set of proofs will be sent to the corresponding author, who is requested to return it to the Editor within 48 hours of receipt. Please stick to correcting typos and errors only, re-writing the text at this stage is not possible.

Since the journal is an Open Access one, authors of accepted manuscripts are requested to pay an **article processing charge of € 600.00 (incl. VAT)** to cover the publishing costs of their paper.

Corresponding authors from the following countries are entitled to **discounts**, based on country of the funding agency:

- World Bank Lower-middle-income economies: 50%
http://data.worldbank.org/about/country-classifications/country-and-lending-groups#Lower_middle_income
- World Bank Low-income economies: 100%
http://data.worldbank.org/about/country-classifications/country-and-lending-groups#Low_income
- Discount for Editorial Board / Advisory Board members: 50%

Once your paper is accepted for publication in *European Journal of Microbiology and Immunology* you will be requested to submit a License Agreement and pay the applicable article processing charge (APC) in our APC system at <http://apc.akademai.hu/>. Article processing will only commence after the amount due has been remitted to our

account. (Please note that there are no submission or peer review charges, the only applicable fee is the article processing fee for authors of accepted papers.)

Open Access policy of the journal includes the **free and unrestricted self-archiving** of the final published version of papers on the Author's webpage or in the Author's institutional repository with open or restricted access. When self-archiving or communicating a paper via e-mail, the Author should quote the correct citation and enclose a link to the published article ([https://doi.org/\[DOI of the Article without brackets\]](https://doi.org/[DOI of the Article without brackets])).

Advantages of the Open Access model:

- Increased readership without limitations.
- Readers will find the final, official version on a credible site.
- More accurate citations to the article in greater numbers.
- Copyright and publishing rights (other than the right of first publishing) shall be retained by the author under the Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC)
- Compliant with the requirements of research funds (NIH, Wellcome, OTKA, etc.)